Protein S100 beta and Melanoma Inhibitory Activity (MIA): A prospective study of their clinical value for the early detection of metastasis in malignant melanoma;Protéine S100 béta et Melanoma Inhibitory Activity (MIA) sériques: Étude prospective de leur valeur pour la détection précoce de métastases dans le mélanome

Annales de Dermatologie et de Venereologie

Volumn 134, Issue 6-7, 2007, Pages 535-540

  Loppin, M ^a,d   Quillien, V ^b   Adamski, H ^a   Ollivier, I ^a   Garlantezec R ^c   Chevrant Breton, J ^a  

^a PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^b CENTRE EUGÈNE MARQUIS   (France)

^c CHU MORVAN   (France)

^d CH Saint Brieuc   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN S 100; PROTEIN S100 BETA; UNCLASSIFIED DRUG;

ARTICLE; BLOOD SAMPLING; CANCER DIAGNOSIS; CANCER STAGING; CELL CULTURE; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA; MELANOMA INHIBITING ACTIVITY; METASTASIS; SENSITIVITY AND SPECIFICITY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; EARLY DIAGNOSIS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX PROTEINS; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM PROTEINS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; S100 PROTEINS; SENSITIVITY AND SPECIFICITY; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 34547759902     PISSN: 01519638     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0151-9638(07)89264-7     Document Type: Article

References (29)

1. Moore BW. A soluble protein characteristic of the nervous system. Biochem Biophys Res 1965;19:739-44.
2. Zimmer DB, Cornwall EH, Landar A, Song W. The S100 protein family: history, function, and expression. Brain Res Bulletin 1995;37:417-29.
3. Meurer M, Szeimies R. M. Serummarker des malignen Melanoms. Hautarzt 2005;56:173-86.
4. Bogdahn U, Apfel R, Hahn M, Gerlach M, Behl C, Hoppe J, et al. Autocrine tumor cell growth-inhibiting activities from human malignant melanoma. Cancer Res 1989;49:5358-63.
5. Bosserhoff AK, Buettner R. Establishing the protein MIA (melanoma inhibitory activity) as a marker for chondrocyte differentiation. Biomaterials 2003;24:3229-34.
6. Hau P, Ruemmele P, Kunz-Schughart LA. Expression levels of melanoma inhibitory activity correlate with time to progression in patients with high-grade glioma. Oncol Rep 2004;12:1355-64.
7. Wagner V, Rudi J, Naher H, Stremmel W. Seropositivity for MIA and S100 in patients with gastro-intestinal carcinomas. Med Oncol 2000;17: 35-8.
8. Bosserhoff AK, Buettner R. Expression, function and clinical relevance of MIA (melanoma inhibitory activity). Histol Histopathol 2002;17:289-300.
9. Brouard M, Quillien V, Ollivier I, Lesimple T, Adamski H, Chevrant-Breton J. Protéine S100B sérique et stade du mélanome cutané : étude prospective. Ann Dermatol Venereol 2000;127:56-9.
10. Spiessl B, Beahrs OH, Hermanl P, Hutter RV, Scheibe O, Sobin LH. TNM atlas: illustrated guide to the TNM/pTNM classification of malignant tumors. 3rd ed. Berlin: Springer-Verlag, 1992.
11. Bach CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001;19:3635-48.
12. Schultz ES, Diepgen TL, Von Den Driesch P. Clinical and prognostic relevance of serum S-100B protein in malignant melanoma. Br J Dermatol 1998;138:426-30.
13. Schmitz C, Brenner W, Henze E, Christophers E, Hauschild A. Comparative study on the clinical use of protein S100B and MIA (melanoma-inhibitory activity) in melanoma patients. Anticancer Res 2000;20:5059-64.
14. Deichmann M, Benner A, Bock M, Jäckel A, Uhl K, Waldmann V, et al. S100-Beta, Melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from non progressive AJCC stage IV melanoma. J Clin Oncol 1999;17:1891-6.
15. Meral R, Duranyildiz D, Tas F, Camlica H, Yasasever V, Kurul S, Dalay N. Prognostic significance of melanoma inhibiting activity levels in malignant melanoma. Melanoma Res 2001;11:627-32.
16. Garbe C, Leiter U, Ellwanger U, Blaheta HJ, Meier F, Rassner G, et al. Diagnostic value and pronostic significance of protein S-100B, melanoma-inhibitory activity, and tyrosinase/MART-1 Reverse transcription- polymerase chain reaction in the follow-up of high-risk melanoma patients. Cancer 2003;97:1737-45.
17. Djukanovic D, Hofmann U, Sucker A, Rittgen W, Schadendorf D. Comparison of S100 protein and MIA protein as serum marker for malignant melanoma. Anticancer Res 2000;20:2203-8.
18. Bosserhoff AK, Dreau D, Hein R, Landthaler M, Holder WD, Buettner R. Melanoma inhibitory activity (MIA), a serological marker of malignant melanoma. Recent Results Cancer Res 2001;158:158-68.
19. Deichmann M, Benner A, Kuner N, Wacker J, Waldmann V, Näher H. Are responses to therapy of metastasized malignant melanoma reflected by decreasing serum values of S100B or melanoma inhibitory activity (MIA)? Melanoma Res 2001;11:291-6.
20. Hamberg AP, Korse CM, Bonfrer JM, Gast GC. Serum S100B is suitable for prediction and monitoring of response to chemoimmunotherapy in metastatic malignant melanoma. Melanoma Res 2003;13:45-9.
21. Smit LH, Korse CM, Hart AA, Bonfrer JM, Haanen JB, Kerst JM, et al. Normal value of serum S-100B predict prolonged survival for stage IV melanoma patients. Eur J Cancer 2005;41:386-92.
22. Kaskel P, Berking C, Sander S, Volkenandt M, Peter RU, Krähn G, et al. S100 protein in peripheral blood: a maker for melanoma metastases. J Am Acad Dermatol 1999;41:962-9.
23. Jury CS, McAllister EJ, McKie RM. Rising levels of serum S100 protein precede other evidence of disease progression in patients with malignant melanoma. Br J Dermatol 2000;143:269-74.
24. Schlagenhauff B, Schittek B, Ellwanger U, Stroebel W, Blum A, Schwarz M, et al. Significance of serum protein S100 levels in screening for melanoma metastasis: does protein S100 enable early detection of melanoma recurrence? Melanoma Res 2000;10:451-9.
25. Juergensen A, Holzapfel U, Hein R, Stolz W, Buettner R, Bosserhoff AK. Comparison of two prognostic markers for malignant melanoma: MIA and S100B. Tumor Biol 2001;22:54-8.
26. Dornier C, Dousset B, Legras B, Barbaud A, Schmutz JL. Protéine S-100B et MIA (melanoma inhibiting activity) sériques. Étude prospective de leur valeur comme marqueur de progression du mélanome. Ann Dermatol Venereol 2002;129:739-40.
27. Matsushita Y, Hatta N, Wakamatsu K, Takehara K, Ito S, Takata M. Melanoma inhibitory activity (MIA) as a serum marker for early detection of post-surgical relapse in melanoma patients:comparison with 5-S0cysteinyldopa. Melanoma Res 2002;12:319-23
28. Tas F, Yasasever V, Duranyildiz D, Camlica H, Ustuner Z, Aydiner A, et al. Clinical value of protein S100 and melanoma-inhibitory activity (MIA) in malignant melanoma. Am J Clin Oncol 2004;27:225-8.
29. Smit LH, Korse CM, Bonfrer JM. Comparison of four different assays for determination of serum S-100B. Int J Biol Markers 2005;20:34-42.